Bioprocessing White Papers

  1. Using Plant Peptones To Boost Plasmid Yield And Induction 2/12/2026

    Uncover how Nu‑Tek’s plant-based peptones support E. coli growth, plasmid yield, and controlled induction, offering a sustainable, animal-free alternative for biopharmaceutical cell culture.

  2. FIH: Reach Milestones Sooner With A Technology-Driven Approach 2/12/2026

    Accelerate your path to IND and FiH with AI-driven design, advanced cell line engineering, and intensified processes delivering high titers in 9–14 months.

  3. Digital Solutions Enhance Pharmaceutical Manufacturing Performance 2/6/2026

    Personalised therapies and advanced technologies are reshaping manufacturing. Explore how intelligent automation can improve flexibility, strengthen data integrity, and accelerate production.

  4. Activate Advanced Contamination Control Technology To Safeguard Your Cell Therapy 2/6/2026

    The most common contamination risks in cell therapy manufacturing are open processes that leverage different products, inflexible instruments, labor intensive workflows, lack of in-line monitoring, and zero failure tolerance.

  5. Smart Scaling For Cell And Gene Therapies 2/5/2026

    To meet patient demand, advanced therapy manufacturing processes must be commercial ready. CGT sponsors can mitigate risk and protect viability by partnering with a CDMO that prioritizes scalability.

  6. Bispecific Antibodies Unleashed 2/4/2026

    Explore how leveraging expert CDMO partnerships can streamline the development process and enhance the efficacy of your bispecific antibody therapies.

  7. The Current And Future Value Of mRNA Vaccines And Therapeutics 2/4/2026

    Discover how decades of research have propelled mRNA technology to the forefront of therapeutic development and learn how our expertise is advancing mRNA drug development.

  8. The Benefits Of End-To-End Formulation And Fill/Finish Of Biologics 2/4/2026

    Proper formulation development has a huge impact on whether a technology transfer to clinical phase fill/finish is successful. Review the challenges of transitioning a promising drug candidate.

  9. Leveraging Efficiency From CLD To Clinical Manufacturing Of mAbs 2/4/2026

    Discover how our efficient strategies can propel your mAb from discovery to clinical manufacturing in as little as 18 months.

  10. Leveraging The Immunological Diversity Of The Pentamice® Platform For Covid-19 Antibody Discovery 2/4/2026

    Consider this alternative immunization approach — the PentaMice platform, a collection of five wildtype mouse strains bred in-house for increased MHC class II diversity — and how we're leveraging it for COVID-19 antibody discovery.